Profiles

Keywords
Last Name
Institution

Nina Paleologos

TitleProfessor
InstitutionRush University, Rush Medical College
DepartmentNeurological Sciences
AddressChicago IL 60612
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    My Scopus ID is 6602195753.


    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Lillehei KO, Kalkanis SN, Liau LM, Mydland DE, Olson J, Paleologos NA, Ryken T, Johnson T, Scullin E. Rationale and design of the 500-patient, 3-year, and prospective Vigilant ObservatIon of GlIadeL WAfer ImplaNT registry. CNS Oncol. 2018 Apr; 7(2):CNS08. PMID: 29206049.
      View in: PubMed
    2. Thomas AA, Abrey LE, Terziev R, Raizer J, Martinez NL, Forsyth P, Paleologos N, Matasar M, Sauter CS, Moskowitz C, Nimer SD, DeAngelis LM, Kaley T, Grimm S, Louis DN, Cairncross JG, Panageas KS, Briggs S, Faivre G, Mohile NA, Mehta J, Jonsson P, Chakravarty D, Gao J, Schultz N, Brennan CW, Huse JT, Omuro A. Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma. Neuro Oncol. 2017 Oct 01; 19(10):1380-1390. PMID: 28472509.
      View in: PubMed
    3. Raizer JJ, Giglio P, Hu J, Groves M, Merrell R, Conrad C, Phuphanich S, Puduvalli VK, Loghin M, Paleologos N, Yuan Y, Liu D, Rademaker A, Yung WK, Vaillant B, Rudnick J, Chamberlain M, Vick N, Grimm S, Tremont-Lukats IW, De Groot J, Aldape K, Gilbert MR. A phase II study of bevacizumab and erlotinib after radiation and temozolomide in MGMT unmethylated GBM patients. J Neurooncol. 2016 Jan; 126(1):185-92. PMID: 26476729; PMCID: PMC4826294.
      View in: PubMed, PubMed Central
    4. Schuster J, Lai RK, Recht LD, Reardon DA, Paleologos NA, Groves MD, Mrugala MM, Jensen R, Baehring JM, Sloan A, Archer GE, Bigner DD, Cruickshank S, Green JA, Keler T, Davis TA, Heimberger AB, Sampson JH. A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study. Neuro Oncol. 2015 Jun; 17(6):854-61. PMID: 25586468; PMCID: PMC4483122.
      View in: PubMed, PubMed Central
    5. Panageas KS, Reiner AS, Iwamoto FM, Cloughesy TF, Aldape KD, Rivera AL, Eichler AF, Louis DN, Paleologos NA, Fisher BJ, Ashby LS, Cairncross JG, Urgoiti GB, Wen PY, Ligon KL, Schiff D, Robins HI, Rocque BG, Chamberlain MC, Mason WP, Weaver SA, Green RM, Kamar FG, Abrey LE, DeAngelis LM, Jhanwar SC, Rosenblum MK, Lassman AB. Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumors. Neuro Oncol. 2014 Nov; 16(11):1541-6. PMID: 24997140; PMCID: PMC4201067.
      View in: PubMed, PubMed Central
    6. Dafer RM, Paleologos N, Lynch D. Intravenous thrombolysis for ischemic stroke in recurrent oligodendroglioma: a case report. J Stroke Cerebrovasc Dis. 2014 May-Jun; 23(5):1235-8. PMID: 24103669.
      View in: PubMed
    7. Paleologos NA, Merrell RT. Anaplastic glioma. Curr Treat Options Neurol. 2012 Aug; 14(4):381-90. PMID: 22665140.
      View in: PubMed
    8. Panageas KS, Iwamoto FM, Cloughesy TF, Aldape KD, Rivera AL, Eichler AF, Louis DN, Paleologos NA, Fisher BJ, Ashby LS, Cairncross JG, Roldán Urgoiti GB, Wen PY, Ligon KL, Schiff D, Robins HI, Rocque BG, Chamberlain MC, Mason WP, Weaver SA, Green RM, Kamar FG, Abrey LE, Deangelis LM, Jhanwar SC, Rosenblum MK, Lassman AB. Initial treatment patterns over time for anaplastic oligodendroglial tumors. Neuro Oncol. 2012 Jun; 14(6):761-7. PMID: 22661585; PMCID: PMC3367843.
      View in: PubMed, PubMed Central
    9. Pope WB, Qiao XJ, Kim HJ, Lai A, Nghiemphu P, Xue X, Ellingson BM, Schiff D, Aregawi D, Cha S, Puduvalli VK, Wu J, Yung WK, Young GS, Vredenburgh J, Barboriak D, Abrey LE, Mikkelsen T, Jain R, Paleologos NA, Rn PL, Prados M, Goldin J, Wen PY, Cloughesy T. Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study. J Neurooncol. 2012 Jul; 108(3):491-8. PMID: 22426926; PMCID: PMC3997502.
      View in: PubMed, PubMed Central
    10. Lassman AB, Iwamoto FM, Cloughesy TF, Aldape KD, Rivera AL, Eichler AF, Louis DN, Paleologos NA, Fisher BJ, Ashby LS, Cairncross JG, Roldán GB, Wen PY, Ligon KL, Schiff D, Robins HI, Rocque BG, Chamberlain MC, Mason WP, Weaver SA, Green RM, Kamar FG, Abrey LE, DeAngelis LM, Jhanwar SC, Rosenblum MK, Panageas KS. International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors. Neuro Oncol. 2011 Jun; 13(6):649-59. PMID: 21636710; PMCID: PMC3107101.
      View in: PubMed, PubMed Central
    11. Wefel JS, Cloughesy T, Zazzali JL, Zheng M, Prados M, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Das A, Friedman HS. Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol. 2011 Jun; 13(6):660-8. PMID: 21558074; PMCID: PMC3107095.
      View in: PubMed, PubMed Central
    12. Vredenburgh JJ, Cloughesy T, Samant M, Prados M, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Das A, Friedman HS. Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study. Oncologist. 2010; 15(12):1329-34. PMID: 21147867; PMCID: PMC3227925.
      View in: PubMed, PubMed Central
    13. Prados M, Cloughesy T, Samant M, Fang L, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Das A, Friedman HS. Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol. 2011 Jan; 13(1):143-51. PMID: 21084434; PMCID: PMC3018914.
      View in: PubMed, PubMed Central
    14. Kalkanis SN, Kondziolka D, Gaspar LE, Burri SH, Asher AL, Cobbs CS, Ammirati M, Robinson PD, Andrews DW, Loeffler JS, McDermott M, Mehta MP, Mikkelsen T, Olson JJ, Paleologos NA, Patchell RA, Ryken TC, Linskey ME. The role of surgical resection in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2010 Jan; 96(1):33-43. PMID: 19960230; PMCID: PMC2808516.
      View in: PubMed, PubMed Central
    15. Mehta MP, Paleologos NA, Mikkelsen T, Robinson PD, Ammirati M, Andrews DW, Asher AL, Burri SH, Cobbs CS, Gaspar LE, Kondziolka D, Linskey ME, Loeffler JS, McDermott M, Olson JJ, Patchell RA, Ryken TC, Kalkanis SN. The role of chemotherapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2010 Jan; 96(1):71-83. PMID: 19960229; PMCID: PMC2808518.
      View in: PubMed, PubMed Central
    16. Linskey ME, Andrews DW, Asher AL, Burri SH, Kondziolka D, Robinson PD, Ammirati M, Cobbs CS, Gaspar LE, Loeffler JS, McDermott M, Mehta MP, Mikkelsen T, Olson JJ, Paleologos NA, Patchell RA, Ryken TC, Kalkanis SN. The role of stereotactic radiosurgery in the management of patients with newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2010 Jan; 96(1):45-68. PMID: 19960227; PMCID: PMC2808519.
      View in: PubMed, PubMed Central
    17. Gaspar LE, Mehta MP, Patchell RA, Burri SH, Robinson PD, Morris RE, Ammirati M, Andrews DW, Asher AL, Cobbs CS, Kondziolka D, Linskey ME, Loeffler JS, McDermott M, Mikkelsen T, Olson JJ, Paleologos NA, Ryken TC, Kalkanis SN. The role of whole brain radiation therapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2010 Jan; 96(1):17-32. PMID: 19960231; PMCID: PMC2808517.
      View in: PubMed, PubMed Central
    18. Olson JJ, Paleologos NA, Gaspar LE, Robinson PD, Morris RE, Ammirati M, Andrews DW, Asher AL, Burri SH, Cobbs CS, Kondziolka D, Linskey ME, Loeffler JS, McDermott M, Mehta MP, Mikkelsen T, Patchell RA, Ryken TC, Kalkanis SN. The role of emerging and investigational therapies for metastatic brain tumors: a systematic review and evidence-based clinical practice guideline of selected topics. J Neurooncol. 2010 Jan; 96(1):115-42. PMID: 19957013; PMCID: PMC2808529.
      View in: PubMed, PubMed Central
    19. Mikkelsen T, Paleologos NA, Robinson PD, Ammirati M, Andrews DW, Asher AL, Burri SH, Cobbs CS, Gaspar LE, Kondziolka D, Linskey ME, Loeffler JS, McDermott M, Mehta MP, Olson JJ, Patchell RA, Ryken TC, Kalkanis SN. The role of prophylactic anticonvulsants in the management of brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2010 Jan; 96(1):97-102. PMID: 19957015; PMCID: PMC2808526.
      View in: PubMed, PubMed Central
    20. Ammirati M, Cobbs CS, Linskey ME, Paleologos NA, Ryken TC, Burri SH, Asher AL, Loeffler JS, Robinson PD, Andrews DW, Gaspar LE, Kondziolka D, McDermott M, Mehta MP, Mikkelsen T, Olson JJ, Patchell RA, Kalkanis SN. The role of retreatment in the management of recurrent/progressive brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2010 Jan; 96(1):85-96. PMID: 19957016; PMCID: PMC2808530.
      View in: PubMed, PubMed Central
    21. Ryken TC, McDermott M, Robinson PD, Ammirati M, Andrews DW, Asher AL, Burri SH, Cobbs CS, Gaspar LE, Kondziolka D, Linskey ME, Loeffler JS, Mehta MP, Mikkelsen T, Olson JJ, Paleologos NA, Patchell RA, Kalkanis SN. The role of steroids in the management of brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2010 Jan; 96(1):103-14. PMID: 19957014; PMCID: PMC2808527.
      View in: PubMed, PubMed Central
    22. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009 Oct 01; 27(28):4733-40. PMID: 19720927.
      View in: PubMed
    23. Mikkelsen T, Doyle T, Anderson J, Margolis J, Paleologos N, Gutierrez J, Croteau D, Hasselbach L, Avedissian R, Schultz L. Temozolomide single-agent chemotherapy for newly diagnosed anaplastic oligodendroglioma. J Neurooncol. 2009 Mar; 92(1):57-63. PMID: 19011763.
      View in: PubMed
    24. Mohile NA, Forsyth P, Stewart D, Raizer JJ, Paleologos N, Kewalramani T, Louis DN, Cairncross JG, Abrey LE. A phase II study of intensified chemotherapy alone as initial treatment for newly diagnosed anaplastic oligodendroglioma: an interim analysis. J Neurooncol. 2008 Sep; 89(2):187-93. PMID: 18458821.
      View in: PubMed
    25. Zeidman LA, Ankenbrandt WJ, Du H, Paleologos N, Vick NA. Growth rate of non-operated meningiomas. J Neurol. 2008 Jun; 255(6):891-5. PMID: 18350353.
      View in: PubMed
    26. Abrey LE, Louis DN, Paleologos N, Lassman AB, Raizer JJ, Mason W, Finlay J, MacDonald DR, DeAngelis LM, Cairncross JG. Survey of treatment recommendations for anaplastic oligodendroglioma. Neuro Oncol. 2007 Jul; 9(3):314-8. PMID: 17435180; PMCID: PMC1907408.
      View in: PubMed, PubMed Central
    27. Abrey LE, Childs BH, Paleologos N, Kaminer L, Rosenfeld S, Salzman D, Finlay JL, Gardner S, Peterson K, Hu W, Swinnen L, Bayer R, Forsyth P, Stewart D, Smith AM, Macdonald DR, Weaver S, Ramsay DA, Nimer SD, DeAngelis LM, Cairncross JG. High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma: long-term follow-up. Neuro Oncol. 2006 Apr; 8(2):183-8. PMID: 16524945; PMCID: PMC1871935.
      View in: PubMed, PubMed Central
    28. Paleologos NA. Chemotherapy for low-grade gliomas. Expert Rev Neurother. 2005 Nov; 5(6 Suppl):S21-4. PMID: 16274267.
      View in: PubMed
    29. Abrey LE, Moskowitz CH, Mason WP, Crump M, Stewart D, Forsyth P, Paleologos N, Correa DD, Anderson ND, Caron D, Zelenetz A, Nimer SD, DeAngelis LM. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. J Clin Oncol. 2003 Nov 15; 21(22):4151-6. PMID: 14615443.
      View in: PubMed
    30. Abrey LE, Childs BH, Paleologos N, Kaminer L, Rosenfeld S, Salzman D, Finlay JL, Gardner S, Peterson K, Hu W, Swinnen L, Bayer R, Forsyth P, Stewart D, Smith AM, Macdonald DR, Weaver S, Ramsey DA, Nimer SD, DeAngelis LM, Cairncross JG. High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma. J Neurooncol. 2003 Nov; 65(2):127-34. PMID: 14686732.
      View in: PubMed
    31. Wurtz R, Paleologos N. La Crosse encephalitis presenting like herpes simplex encephalitis in an immunocompromised adult. Clin Infect Dis. 2000 Oct; 31(4):1113-4. PMID: 11049801.
      View in: PubMed
    32. Cairncross G, Swinnen L, Bayer R, Rosenfeld S, Salzman D, Paleologos N, Kaminer L, Forsyth P, Stewart D, Peterson K, Hu W, Macdonald D, Ramsay D, Smith A. Myeloablative chemotherapy for recurrent aggressive oligodendroglioma. Neuro Oncol. 2000 04; 2(2):114-9. PMID: 11303620; PMCID: PMC1919513.
      View in: PubMed, PubMed Central
    33. Paleologos NA, Macdonald DR, Vick NA, Cairncross JG. Neoadjuvant procarbazine, CCNU, and vincristine for anaplastic and aggressive oligodendroglioma. Neurology. 1999 Sep 22; 53(5):1141-3. PMID: 10496285.
      View in: PubMed
    34. Paleologos NA, Cairncross JG. Treatment of oligodendroglioma: an update. Neuro Oncol. 1999 Jan; 1(1):61-8. PMID: 11550303; PMCID: PMC1919459.
      View in: PubMed, PubMed Central
    35. Bigner DD, Brown MT, Friedman AH, Coleman RE, Akabani G, Friedman HS, Thorstad WL, McLendon RE, Bigner SH, Zhao XG, Pegram CN, Wikstrand CJ, Herndon JE, Vick NA, Paleologos N, Cokgor I, Provenzale JM, Zalutsky MR. Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results. J Clin Oncol. 1998 Jun; 16(6):2202-12. PMID: 9626222.
      View in: PubMed
    36. Peterson K, Paleologos N, Forsyth P, Macdonald DR, Cairncross JG. Salvage chemotherapy for oligodendroglioma. J Neurosurg. 1996 Oct; 85(4):597-601. PMID: 8814162.
      View in: PubMed
    37. Brown MT, Coleman RE, Friedman AH, Friedman HS, McLendon RE, Reiman R, Felsberg GJ, Tien RD, Bigner SH, Zalutsky MR, Zhao XG, Wikstrand CJ, Pegram CN, Herndon JE, Vick NA, Paleologos N, Fredericks RK, Schold SC, Bigner DD. Intrathecal 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: phase I trial results. Clin Cancer Res. 1996 Jun; 2(6):963-72. PMID: 9816257.
      View in: PubMed
    38. Halperin EC, Herndon J, Schold SC, Brown M, Vick N, Cairncross JG, Macdonald DR, Gaspar L, Fischer B, Dropcho E, Rosenfeld S, Morowitz R, Piepmeier J, Hait W, Byrne T, Salter M, Imperato J, Khandekar J, Paleologos N, Burger P, Bentel GC, Friedman A. A phase III randomized prospective trial of external beam radiotherapy, mitomycin C, carmustine, and 6-mercaptopurine for the treatment of adults with anaplastic glioma of the brain. CNS Cancer Consortium. Int J Radiat Oncol Biol Phys. 1996 Mar 01; 34(4):793-802. PMID: 8598355.
      View in: PubMed
    39. Vick NA, Paleologos NA. External beam radiotherapy: hard facts and painful realities. J Neurooncol. 1995; 24(1):93-5. PMID: 8523083.
      View in: PubMed
    40. Imperato JP, Paleologos NA, Vick NA. Effects of treatment on long-term survivors with malignant astrocytomas. Ann Neurol. 1990 Dec; 28(6):818-22. PMID: 2178330.
      View in: PubMed
    41. Paleologos NA, Groothuis DR. The role of the blood-brain barrier in movement disorders. Clin Neuropharmacol. 1990 Apr; 13(2):129-46. PMID: 2183934.
      View in: PubMed
    Paleologos's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (162) concept(s)
    _
    Similar People Expand Description
    See all (60) people
    _
    Same Department Expand Description
    Search Department